Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology.
The last earnings update was 55 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sierra Oncology. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Sierra Oncology's earnings available for a low price, and how does
this compare to other companies in the same industry?
Sierra Oncology's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Sierra Oncology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Sierra Oncology's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Nicholas R. Glover, also known as Nick, Ph.D. has been Chief Executive Officer, President and Director of Sierra Oncology, Inc. since September 2014 and provided consulting services from July 2014 to August 2014. Dr. Glover served as the President and Chief Executive Officer of YM BioSciences Inc. from November 2010 to February 2013. Dr. Glover served as the Chief Operating Officer of YM BioSciences Inc. from June 7, 2010 to November 2010. He served as President and Chief Executive Officer of Viventia Biotechnologies Inc. from January 8, 2004 to June 2008. He was responsible for all aspects of biotherapeutic development, including GMP manufacturing and has taken products from discovery, through preclinical development and into global registrational clinical trials, with a specific focus in Oncology. He served as Vice President, Corporate Development of Viventia Biotechnologies Inc. since September 2001 until January 8, 2004. Dr. Glover joined Viventia Biotech Inc., in September 2000 and has had responsibility for all aspects of its business development, including financing, corporate partnering and strategic orientation. Dr. Glover has also served as a consultant in the biotechnology and life sciences industries at various times since 2008. Prior to joining Viventia Biotech Inc., he served as an Investment Manager in MDS Capital Corp., where he had responsibilities included sourcing, negotiating and completed venture capital investments in the biotechnology sector. He has been a Non-Executive Director of MEI Pharma, Inc. since June 11, 2013. He served as a Director of Viventia Biotechnologies Inc. since June 2004. He has been a Director of YM BioSciences Inc. since November 18, 2010. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., an M.Sc. in Chemistry from the University of British Columbia, Canada and a Ph.D. in Chemistry from Simon Fraser University, Canada.
Nick's compensation has been consistent with company performance over the past year.
Nick's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Sierra Oncology management team is about average.
Chief Development Officer
Chief Medical Officer
Chief Financial Officer
Senior Vice President of Technical Operations
Chief Scientific Officer
Senior Vice President of Human Resources & Administration
Senior Vice President of Clinical Operations
Senior Vice President of Program Management
Senior Vice President of Drug Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Sierra Oncology board of directors is about average.
Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control. The company is also advancing SRA737, which is being investigated in two Phase 1/2 clinical trials primarily focused on patients with ovarian cancer; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.